Boron neutron capture therapy (BNCT): Implications of neutron beam and boron compound characteristics
- 12 July 1999
- journal article
- research article
- Published by Wiley in Medical Physics
- Vol. 26 (7) , 1237-1244
- https://doi.org/10.1118/1.598618
Abstract
The potential efficacy of boron neutron capture therapy (BNCT) for malignant glioma is a significant function of epithermal-neutron beam biophysical characteristics as well as boron compound biodistribution characteristics. Monte Carlo analyses were performed to evaluate the relative significance of these factors on theoretical tumor control using a standard model. The existing, well-characterized epithermal-neutron sources at the Brookhaven Medical Research Reactor (BMRR), the Petten High Flux Reactor (HFR), and the Finnish Research Reactor (FiR-1) were compared. Results for a realistic accelerator design by the E. O. Lawrence Berkeley National Laboratory (LBL) are also compared. Also the characteristics of the compound p-Boronophenylaline Fructose (BPA-F) and a hypothetical next-generation compound were used in a comparison of the BMRR and a hypothetical improved reactor. All components of dose induced by an external epithermal-neutron beam fall off quite rapidly with depth in tissue. Delivery of dose to greater depths is limited by the healthy-tissue tolerance and a reduction in the hydrogen-recoil and incident gamma dose allow for longer irradiation and greater dose at a depth. Dose at depth can also be increased with a beam that has higher neutron energy (without too high a recoil dose) and a more forward peaked angular distribution. Of the existing facilities, the FiR-1 beam has the better quality (lower hydrogen-recoil and incident gamma dose) and a penetrating neutron spectrum and was found to deliver a higher value of Tumor Control Probability (TCP) than other existing beams at shallow depth. The greater forwardness and penetration of the HFR the FiR-1 at greater depths. The hypothetical reactor and accelerator beams outperform at both shallow and greater depths. In all cases, the hypothetical compound provides a significant improvement in efficacy but it is shown that the full benefit of improved compound is not realized until the neutron beam is fully optimized.Keywords
Funding Information
- U.S. Department of Energy
- U.S. Department of Energy (DE‐AC07‐94ID13223)
This publication has 10 references indexed in Scilit:
- Boron Neutron-Capture Therapy (BNCT) for Glioblastoma Multiforme (GBM) Using the Epithermal Neutron Beam at the Brookhaven National LaboratoryInternational Journal of Radiation Oncology*Biology*Physics, 1998
- An improved neutron collimator for brain tumor irradiations in clinical boron neutron capture therapyMedical Physics, 1996
- Selective ablation of rat brain tumors by boron neutron capture therapyInternational Journal of Radiation Oncology*Biology*Physics, 1994
- Enhancement of the epithermal neutron beam used for boron neutron capture therapyInternational Journal of Radiation Oncology*Biology*Physics, 1994
- Clinical results of long-surviving brain tumor patients who underwent boron neutron capture therapyInternational Journal of Radiation Oncology*Biology*Physics, 1994
- Epithermal BNCT Neutron Beam Design for a Triga II ReactorPublished by Springer Nature ,1993
- RBE in Normal Tissue StudiesPublished by Springer Nature ,1992
- Physics Design for the Brookhaven Medical Research Reactor Epithermal Neutron SourcePublished by Springer Nature ,1990
- Updated version of the DOT 4 one- and two-dimensional neutron/photon transport codePublished by Office of Scientific and Technical Information (OSTI) ,1982
- The statistics of dose/cure relationships for irradiated tumours. Part I.The British Journal of Radiology, 1980